The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Development and Independent Validation of a Prognostic Assay for Stage II Colon Cancer Using Formalin-Fixed Paraffin-Embedded Tissue
Abstract
Purpose: Current prognostic factors are poor at identifying patients at risk of disease recurrence after surgery for stage II colon cancer. Here we describe a DNA microarray–based prognostic assay using clinically relevant formalin-fixed paraffin-embedded (FFPE) samples. Patients and Methods: A gene signature was developed from a balanced set of 73 patients with recurrent disease (high risk) and 142 patients with no recurrence (low risk) within 5 years of surgery. Results: The 634–probe set signature identified high-risk patients with a hazard ratio (HR) of 2.62 (P < .001) during cross validation of the training set. In an independent validation set of 144 samples, the signature identified high-risk patients with an HR of 2.53 (P < .001) for recurrence and an HR of 2.21 (P = .0084) for cancer-related death. Additionally, the signature was shown to perform independently from known prognostic factors (P < .001). Conclusion: This gene signature represents a novel prognostic biomarker for patients with stage II colon cancer that can be applied to FFPE tumor samples.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gene selection for cancer classification using support vector machines
Guyon, I., Weston, J., Barnhill, S., & Vapnik, V. (2002) · Machine Learning · doi:10.1023/a:1012487302797 · Cited by 9,954
SIMPLS: An alternative approach to partial least squares regression
de Jong, S. (1993) · Chemometrics and Intelligent Laboratory Systems · doi:10.1016/0169-7439(93)85002-x · Cited by 1,905
Cited by
Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer
Mármol, I., Sánchez-de-Diego, C., Pradilla Dieste, A., Cerrada, E., & Rodriguez Yoldi, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18010197 · Cited by 1,525
Dangaj, D., Bruand, M., Grimm, A. J., Ronet, C., Barras, D., Duttagupta, P. A., Lanitis, E., Duraiswamy, J., Tanyi, J. L., Benencia, F., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.05.004 · Cited by 875
Zhang, J.-X., Song, W., Chen, Z.-H., Wei, J.-H., Liao, Y.-J., Lei, J., Hu, M., Chen, G.-Z., Liao, B., Lu, J., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70491-1 · Cited by 544
Yang, X., Zhang, S., He, C., Xue, P., Zhang, L., He, Z., Zang, L., Feng, B., Sun, J., & Zheng, M. (2020) · Molecular Cancer · doi:10.1186/s12943-020-1146-4 · Cited by 513
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
Zhu, G., Pei, L., Xia, H., Tang, Q., & Bi, F. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01441-4 · Cited by 482
“Although many advanced management strategies, including improved surgical techniques and , modified adjuvant therapies, and have achieved favorable effects on the treatment of CRC, the mortality of CRC is still high on due to postoperative recurrence and metastasis [2].”
BackgroundVogel, J. D., Felder, S. I., Bhama, A. R., Hawkins, A. T., Langenfeld, S. J., Shaffer, V. O., Thorsen, A. J., Weiser, M. R., Chang, G. J., Lightner, A. L., et al. (2022) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000002323 · Cited by 401
Duffy, M. J., Lamerz, R., Haglund, C., Nicolini, A., Kalousová, M., Holubec, L., & Sturgeon, C. (2014) · International Journal of Cancer · doi:10.1002/ijc.28384 · Cited by 360
Personalizing Colon Cancer Adjuvant Therapy: Selecting Optimal Treatments for Individual Patients
Dienstmann, R., Salazar, R., & Tabernero, J. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0213 · Cited by 343
Prognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges
Koncina, E., Haan, S., Rauh, S., & Letellier, E. (2020) · Cancers · doi:10.3390/cancers12020319 · Cited by 259
DeepCC: a novel deep learning-based framework for cancer molecular subtype classification
Gao, F., Wang, W., Tan, M., Zhu, L., Zhang, Y., Fessler, E., Vermeulen, L., & Wang, X. (2019) · Oncogenesis · doi:10.1038/s41389-019-0157-8 · Cited by 226
Lightbody, G., Haberland, V., Browne, F., Taggart, L., Zheng, H., Parkes, E., & Blayney, J. K. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bby051 · Cited by 173
Dunne, P. D., Alderdice, M., O'Reilly, P. G., Roddy, A. C., McCorry, A. M. B., Richman, S., Maughan, T., McDade, S. S., Johnston, P. G., Longley, D. B., et al. (2017) · Nature Communications · doi:10.1038/ncomms15657 · Cited by 94
Self-citationBCL-2 system analysis identifies high-risk colorectal cancer patients
Lindner, A. U., Salvucci, M., Morgan, C., Monsefi, N., Resler, A. J., Cremona, M., Curry, S., Toomey, S., O'Byrne, R., Bacon, O., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-312287 · Cited by 50
Self-citationSchell, M. J., Yang, M., Missiaglia, E., Delorenzi, M., Soneson, C., Yue, B., Nebozhyn, M. V., Loboda, A., Bloom, G., & Yeatman, T. J. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0143 · Cited by 42
Corry, S. M., McCorry, A. M., Lannagan, T. R., Leonard, N. A., Fisher, N. C., Byrne, R. M., Tsantoulis, P., Cortes-Lavaud, X., Amirkhah, R., Redmond, K. L., et al. (2022) · Gut · doi:10.1136/gutjnl-2021-326183 · Cited by 18
Self-citation
Metadata
- Authors
- Kennedy, R. D., Bylesjo, M., Kerr, P., Davison, T., Black, J. M., Kay, E. W., Holt, R. J., Proutski, V., Ahdesmaki, M., Farztdinov, V., Goffard, N., Hey, P., McDyer, F., Mulligan, K., Mussen, J., O'Brien, E., Oliver, G., Walker, S. M., Mulligan, J. M., Wilson, C., Winter, A., O'Donoghue, D., Mulcahy, H., O'Sullivan, J., Sheahan, K., Hyland, J., Dhir, R., Bathe, O. F., Winqvist, O., Manne, U., Shanmugam, C., Ramaswamy, S., Leon, E. J., Smith, W. I., McDermott, U., Wilson, R. H., Longley, D., Marshall, J., Cummins, R., Sargent, D. J., Johnston, P. G., & Harkin, D. P.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-12-10
- Volume
- 29
- Issue
- 35
- Pages
- 4620-4626
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2170468505
- Cited by
- 190
- References
- 2
- FWCI
- 6.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.